What are the common intravenous agents used to support blood pressure in adult intensive care unit patients?

Common Intravenous Drugs for Blood Pressure Support in Critical Care

Norepinephrine is the first-line vasopressor for blood pressure support in adult ICU patients with shock, targeting a mean arterial pressure (MAP) of 65 mmHg 1, 2.

First-Line Agent: Norepinephrine

Norepinephrine stands as the gold standard based on strong guideline recommendations from the 2016 Surviving Sepsis Campaign 1. This recommendation is supported by:

• Strong evidence (Grade 1B) demonstrating superiority over dopamine with lower mortality, reduced heart rate, and fewer arrhythmias 3
• Appropriate for most shock states including septic, cardiogenic, and vasodilatory shock 4
• Should be titrated to achieve MAP ≥65 mmHg as the initial target 1

Second-Line Agents When Norepinephrine Alone Is Insufficient

When norepinephrine fails to achieve adequate blood pressure or requires excessively high doses, add one of the following:

Vasopressin (0.03 units/min)

• Add to norepinephrine (not as monotherapy) to raise MAP or reduce norepinephrine requirements 1
• Moderate quality evidence supports norepinephrine-sparing effects 2
• Associated with lower arrhythmia risk but higher digital ischemia risk 3
• Do not exceed 0.03-0.04 units/min; higher doses reserved for salvage therapy 1

Epinephrine

• Second choice when additional agent needed beyond norepinephrine 1
• Can be added to or substituted for norepinephrine (Grade 2B recommendation) 1
• Useful when inotropic support also needed 4

Angiotensin II

• Emerging option for norepinephrine-sparing effects 2
• May be particularly useful for rapid resuscitation in profoundly hypotensive patients 5

Agents with Limited or Specific Roles

Dopamine

• Avoid as first-line due to increased adverse effects 1, 3
• Only consider in highly selected patients with low tachyarrhythmia risk and absolute/relative bradycardia 1
• Strong recommendation against use for renal protection 1

Phenylephrine

• Not recommended except when norepinephrine causes serious arrhythmias or cardiac output is known to be high 1
• Pure alpha-agonist without inotropic effects

Inotropic Support

Dobutamine

• First-line inotrope when myocardial dysfunction present despite adequate blood pressure 2, 4
• Add when tissue perfusion remains inadequate despite achieving MAP targets 4
• Increases cardiac output to meet tissue oxygen demands

Critical Dosing Considerations

Recent data shows maximum norepinephrine-equivalent doses vary widely (90th percentile: 0.7 µg/kg/min), with some patients receiving up to 7.3 µg/kg/min 6. However:

• No absolute dosing cutoff precludes survival 6
• Titrate to minimal effective dose and wean promptly 2
• Close hemodynamic monitoring essential given narrow therapeutic window 2

Common Pitfalls to Avoid

• Never use vasopressin as sole initial vasopressor - it must be added to norepinephrine 1
• Avoid high-dose dopamine - associated with excessive tachyarrhythmias 1, 3
• Don't delay vasopressor initiation - administer simultaneously with fluid resuscitation to minimize hypotension duration 5
• Monitor for excessive vasoconstriction - can cause organ ischemia/infarction, particularly digital ischemia with vasopressin 3

Algorithmic Approach

1. Start norepinephrine targeting MAP ≥65 mmHg
2. If inadequate response: Add vasopressin (up to 0.03 U/min) OR epinephrine
3. If myocardial dysfunction present: Add dobutamine for inotropic support
4. If refractory hypotension: Consider angiotensin II for salvage therapy
5. Titrate all agents to minimal effective dose with continuous monitoring

This approach prioritizes mortality reduction and minimizes adverse events while maintaining adequate tissue perfusion 1, 2, 4.